<DOC>
	<DOCNO>NCT01070394</DOCNO>
	<brief_summary>The purpose study examine effectiveness length effect Vyvanse lessen Attention-Deficit/Hyperactivity Disorder symptom adult . The study also investigate safety tolerability Vyvanse adult ADHD .</brief_summary>
	<brief_title>Effectiveness Duration Effect Open Treatment ADHD Patients Treated With Lisdexamfetamine Dimesylate ( Vyvanse )</brief_title>
	<detailed_description>Protocol Summary : Effectiveness Duration Effect Open Treatment Adult ADHD Patients Treated Lisdexamfetamine Dimesylate- LDX ( Vyvanse ) The primary objective study evaluate effectiveness duration effect LDX treatment ADHD symptom adult . The study 12-week open label extension 25 adult participant complete cross-over study adherence/efficacy Adderall Immediate Release ( IR ) vs. Adderall Extended Release ( XR ) . The secondary objective provide information regard tolerability , dose titration LDX adult population ADHD . An additional fifteen participant recruit use advertise previous Mental Health Addictive Behaviour Research Program ( MHADRP ) study offer treatment LDX . All participant diagnose ADHD use Adult Clinician Diagnostic Scale ( ACDS ) . We collect demographic information , administer Scheduled Clinical Interview DSM Disorders ( SCID ) , collect medical history , previous drug therapy , participant physical physician . A coordinator give electrocardiogram ( ECG ) , collect blood sample blood chemistry hematology . Schedule Events : Vyvanse Extension Screening Visit - Consent - Demographics ( need add ? ) - Physical - Medical history ( need add ? ) - Previous drug therapy - Vitals ( Blood Pressure-BP , Heart Rate-HR , Respiration , weight ) - Urine Drug screen - Urine pregnancy test - ECG - Blood sample - SCID - ACDS Visits week 0,1,2,3,4,6,8,10,12 ( every visit ) - ADHD-Rating Scale ( ADHD-RS ) - Adult ADHD Self-Report Scale ( ASRS ) - Clinical Global Impression ( CGI ) - Vitals - Pill count - Adverse Events ( AE ) / Concomitant Medications ( CM ) Visits week 0,1,4,6,12 also administer - Adult ADHD Medication Rebound Scale ( AMRS ) ( AM/PM ) - Adult ADHD Medication Smoothness Effect Scale ( AMSES ) ( AM/PM ) - Wender-Reimherr Adult Attention Deficit Disorder Scale ( WRAADS ) ( AM/PM ) First 4 week treatment dose adjustment period ( 30-70 mg po qAM ) , 4 week establish dose remain remain 8 week treatment .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Amphetamine</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<criteria>1 . At time consent , age 1855 , inclusive . 2 . Meet DSMIV criterion ADHD assess Adult ADHD Clinician Diagnostic Scale ( ACDS ) v1.2 . 3 . Female participant childbearing potential must test negative pregnancy time enrollment base urine pregnancy test agree use reliable method birth control study . Females childbearing potential defined woman surgically sterilize menarche 2 year postmenopause . 4 . Must satisfactory medical assessment clinically significant abnormality determine medical history , physical exam , ECG , clinical laboratory test . 5 . Must able swallow capsule . 6 . Must able begin daily dose study medication morning . 7 . Must ADHD therapies one week ( psychostimulants ) three week ( nonstimulants ) . 8 . In opinion investigator , subject must understand able , willing likely fully comply study procedure restriction . 9 . Must give sign date informed consent accordance Good Clinical Practice ( GCP ) Guidelines . 1 . Participants positive urine drug result Screening . 2 . Anyone meet current DSMIVTR criterion alcohol nonalcohol substance abuse dependence disorder ( exclude nicotine ) . 3 . Participants control depressive anxiety disorder may participate , opinion Principal Investigator , medication interfere safety efficacy assessment . 4 . Participants concurrent chronic acute illness unstable medical condition could , opinion study physician , confound result safety assessment , increase risk subject lead difficulty comply protocol . 5 . Participants hypertension screening , indicate blood pressure read 135/90 heart rate 120bmp . 6 . Female participant childbearing potential test positive pregnancy time enrollment base urine pregnancy test , agree use reliable method birth control study . Females childbearing potential defined woman surgically sterilize menarche 2 year postmenopause . 7 . Participants work night shift another schedule would preclude begin daily dose study medication morning . 8 . Participants investigator 's opinion meet exclusionary criterion specify FDA label Vyvanse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>ADHD</keyword>
	<keyword>Lisdexamfetamine Dimesylate</keyword>
	<keyword>Amphetamine</keyword>
</DOC>